QuantRx Biomedical Corporation (QTXB)
USD 0.0
(400.0%)
USD 0.0
(400.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2022 | - USD | -100.0% |
| 2021 | 2.63 Million USD | 11.25% |
| 2020 | 2.36 Million USD | 14.07% |
| 2019 | 2.07 Million USD | 23.08% |
| 2018 | 1.68 Million USD | 13.38% |
| 2017 | 1.48 Million USD | -12.27% |
| 2016 | 1.69 Million USD | 31.22% |
| 2015 | 1.29 Million USD | 31.43% |
| 2014 | 981.83 Thousand USD | 26.16% |
| 2013 | 778.23 Thousand USD | 72.34% |
| 2012 | 451.55 Thousand USD | 120.73% |
| 2011 | 204.57 Thousand USD | 210.02% |
| 2010 | -185.94 Thousand USD | 44.03% |
| 2009 | -332.21 Thousand USD | -108.51% |
| 2008 | 3.9 Million USD | 507.51% |
| 2007 | 642.75 Thousand USD | 151.14% |
| 2006 | -1.25 Million USD | -34.41% |
| 2005 | -935.11 Thousand USD | -371.81% |
| 2004 | 344.02 Thousand USD | -20.38% |
| 2003 | 432.07 Thousand USD | 2.75% |
| 2002 | 420.49 Thousand USD | 7.82% |
| 2001 | 390 Thousand USD | -2.5% |
| 2000 | 400 Thousand USD | 566.67% |
| 1999 | 60 Thousand USD | 128.57% |
| 1998 | -210 Thousand USD | -320.0% |
| 1997 | -50 Thousand USD | 83.33% |
| 1996 | -300 Thousand USD | 87.8% |
| 1995 | -2.46 Million USD | -28.13% |
| 1994 | -1.92 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q3 | - USD | 0.0% |
| 2023 Q1 | - USD | 0.0% |
| 2023 Q2 | - USD | 0.0% |
| 2022 Q1 | 2.68 Million USD | 2.05% |
| 2022 Q2 | 2.68 Million USD | -0.15% |
| 2022 FY | - USD | -100.0% |
| 2022 Q4 | - USD | -100.0% |
| 2022 Q3 | 2.82 Million USD | 5.4% |
| 2021 Q1 | 2.42 Million USD | 2.57% |
| 2021 FY | 2.63 Million USD | 11.25% |
| 2021 Q4 | 2.63 Million USD | 2.72% |
| 2021 Q3 | 2.56 Million USD | 2.45% |
| 2021 Q2 | 2.5 Million USD | 3.07% |
| 2020 Q4 | 2.36 Million USD | 2.62% |
| 2020 FY | 2.36 Million USD | 14.07% |
| 2020 Q1 | 2.14 Million USD | 3.49% |
| 2020 Q2 | 2.22 Million USD | 3.84% |
| 2020 Q3 | 2.3 Million USD | 3.44% |
| 2019 Q4 | 2.07 Million USD | 3.97% |
| 2019 Q1 | 1.77 Million USD | 5.52% |
| 2019 Q2 | 1.89 Million USD | 6.53% |
| 2019 Q3 | 1.99 Million USD | 5.32% |
| 2019 FY | 2.07 Million USD | 23.08% |
| 2018 FY | 1.68 Million USD | 13.38% |
| 2018 Q1 | 1.6 Million USD | 7.8% |
| 2018 Q4 | 1.68 Million USD | -3.32% |
| 2018 Q3 | 1.74 Million USD | -1.74% |
| 2018 Q2 | 1.77 Million USD | 10.7% |
| 2017 Q3 | 1.93 Million USD | 3.33% |
| 2017 Q1 | 1.78 Million USD | 5.55% |
| 2017 FY | 1.48 Million USD | -12.27% |
| 2017 Q4 | 1.48 Million USD | -23.09% |
| 2017 Q2 | 1.86 Million USD | 4.59% |
| 2016 FY | 1.69 Million USD | 31.22% |
| 2016 Q3 | 1.61 Million USD | -6.81% |
| 2016 Q2 | 1.73 Million USD | 5.27% |
| 2016 Q4 | 1.69 Million USD | 4.99% |
| 2016 Q1 | 1.64 Million USD | 27.4% |
| 2015 FY | 1.29 Million USD | 31.43% |
| 2015 Q4 | 1.29 Million USD | 5.03% |
| 2015 Q1 | 1.05 Million USD | 7.02% |
| 2015 Q2 | 1.03 Million USD | -1.6% |
| 2015 Q3 | 1.22 Million USD | 18.84% |
| 2014 Q3 | 853.5 Thousand USD | 0.61% |
| 2014 Q2 | 848.29 Thousand USD | 0.02% |
| 2014 FY | 981.83 Thousand USD | 26.16% |
| 2014 Q4 | 981.83 Thousand USD | 15.04% |
| 2014 Q1 | 848.1 Thousand USD | 8.98% |
| 2013 FY | 778.23 Thousand USD | 72.34% |
| 2013 Q1 | 501.39 Thousand USD | 11.04% |
| 2013 Q2 | 555.38 Thousand USD | 10.77% |
| 2013 Q3 | 568.07 Thousand USD | 2.29% |
| 2013 Q4 | 778.23 Thousand USD | 37.0% |
| 2012 Q1 | 300.43 Thousand USD | 46.86% |
| 2012 Q3 | 419.19 Thousand USD | 4.81% |
| 2012 Q4 | 451.55 Thousand USD | 7.72% |
| 2012 FY | 451.55 Thousand USD | 120.73% |
| 2012 Q2 | 399.97 Thousand USD | 33.13% |
| 2011 FY | 204.57 Thousand USD | 210.02% |
| 2011 Q4 | 204.57 Thousand USD | 27.39% |
| 2011 Q3 | 160.58 Thousand USD | 16.74% |
| 2011 Q2 | 137.55 Thousand USD | 332.87% |
| 2011 Q1 | 31.77 Thousand USD | 117.09% |
| 2010 Q2 | -84.1 Thousand USD | 46.95% |
| 2010 Q4 | -185.94 Thousand USD | -3216.28% |
| 2010 FY | -185.94 Thousand USD | 44.03% |
| 2010 Q3 | -5607.00 USD | 93.33% |
| 2010 Q1 | -158.52 Thousand USD | 52.28% |
| 2009 Q3 | -507.02 Thousand USD | -110.36% |
| 2009 Q1 | 4.12 Million USD | 5.66% |
| 2009 FY | -332.21 Thousand USD | -108.51% |
| 2009 Q4 | -332.21 Thousand USD | 34.48% |
| 2009 Q2 | 4.89 Million USD | 18.62% |
| 2008 Q4 | 3.9 Million USD | 24.06% |
| 2008 Q1 | 1.3 Million USD | 103.36% |
| 2008 Q2 | 1.95 Million USD | 49.27% |
| 2008 Q3 | 3.14 Million USD | 61.31% |
| 2008 FY | 3.9 Million USD | 507.51% |
| 2007 Q3 | -121.45 Thousand USD | 86.07% |
| 2007 Q4 | 642.75 Thousand USD | 629.23% |
| 2007 Q2 | -871.99 Thousand USD | 67.77% |
| 2007 FY | 642.75 Thousand USD | 151.14% |
| 2007 Q1 | -2.7 Million USD | -115.23% |
| 2006 FY | -1.25 Million USD | -34.41% |
| 2006 Q1 | -1.72 Million USD | -84.58% |
| 2006 Q2 | 797.87 Thousand USD | 146.23% |
| 2006 Q3 | 2.3 Million USD | 189.46% |
| 2006 Q4 | -1.25 Million USD | -154.42% |
| 2005 Q4 | -935.11 Thousand USD | -1069.19% |
| 2005 Q2 | -372.58 Thousand USD | -196.62% |
| 2005 Q3 | -79.98 Thousand USD | 78.53% |
| 2005 Q1 | 385.63 Thousand USD | 12.09% |
| 2005 FY | -935.11 Thousand USD | -371.81% |
| 2004 FY | 344.02 Thousand USD | -20.38% |
| 2004 Q4 | 344.02 Thousand USD | 0.0% |
| 2003 FY | 432.07 Thousand USD | 2.75% |
| 2003 Q4 | 430 Thousand USD | 0.0% |
| 2002 Q1 | 450 Thousand USD | 15.38% |
| 2002 Q4 | 420 Thousand USD | 0.0% |
| 2002 FY | 420.49 Thousand USD | 7.82% |
| 2001 FY | 390 Thousand USD | -2.5% |
| 2001 Q1 | 450 Thousand USD | 12.5% |
| 2001 Q4 | 390 Thousand USD | -11.36% |
| 2001 Q3 | 440 Thousand USD | -2.22% |
| 2001 Q2 | 450 Thousand USD | 0.0% |
| 2000 Q2 | 210 Thousand USD | 177.78% |
| 2000 Q4 | 400 Thousand USD | 233.33% |
| 2000 Q3 | 120 Thousand USD | -42.86% |
| 2000 Q1 | -270 Thousand USD | -550.0% |
| 2000 FY | 400 Thousand USD | 566.67% |
| 1999 Q2 | 310 Thousand USD | 3.33% |
| 1999 Q1 | 300 Thousand USD | 242.86% |
| 1999 Q3 | -50 Thousand USD | -116.13% |
| 1999 Q4 | 60 Thousand USD | 220.0% |
| 1999 FY | 60 Thousand USD | 128.57% |
| 1998 FY | -210 Thousand USD | -320.0% |
| 1998 Q3 | 430 Thousand USD | 53.57% |
| 1998 Q2 | 280 Thousand USD | -26.32% |
| 1998 Q4 | -210 Thousand USD | -148.84% |
| 1998 Q1 | 380 Thousand USD | 860.0% |
| 1997 Q3 | -1.47 Million USD | 29.33% |
| 1997 Q4 | -50 Thousand USD | 96.6% |
| 1997 Q2 | -2.08 Million USD | -173.68% |
| 1997 Q1 | -760 Thousand USD | -153.33% |
| 1997 FY | -50 Thousand USD | 83.33% |
| 1996 Q3 | -70 Thousand USD | -138.89% |
| 1996 Q1 | -920 Thousand USD | 62.6% |
| 1996 FY | -300 Thousand USD | 87.8% |
| 1996 Q2 | 180 Thousand USD | 119.57% |
| 1996 Q4 | -300 Thousand USD | -328.57% |
| 1995 Q4 | -2.46 Million USD | 28.28% |
| 1995 Q1 | -1.07 Million USD | 44.27% |
| 1995 Q2 | -4.38 Million USD | -309.35% |
| 1995 Q3 | -3.43 Million USD | 21.69% |
| 1995 FY | -2.46 Million USD | -28.13% |
| 1994 FY | -1.92 Million USD | 0.0% |
| 1994 Q3 | 90 Thousand USD | -35.71% |
| 1994 Q2 | 140 Thousand USD | 0.0% |
| 1994 Q4 | -1.92 Million USD | -2233.33% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| American Medical Technologies Inc. | 479.63 Thousand USD | 100.0% |
| Ansell Limited | -54.99 Million USD | 100.0% |
| Ansell Limited | -55.1 Million USD | 100.0% |
| BG Medicine, Inc. | - USD | NaN% |
| Biotage AB (publ) | -36.49 Million USD | 100.0% |
| BioLife Sciences Inc. | - USD | NaN% |
| CB Scientific, Inc. | -105.1 Thousand USD | 100.0% |
| Psykey, Inc. | 634.59 Thousand USD | 100.0% |
| ConvaTec Group Plc | 1.2 Billion USD | 100.0% |
| ConvaTec Group Plc | 1.2 Billion USD | 100.0% |
| Encision Inc. | 1.29 Million USD | 100.0% |
| Golden Valley Development, Inc | - USD | NaN% |
| Hear AtLast Holdings, Inc. | 2.3 Million USD | 100.0% |
| Innovative MedTech Inc. | 1.76 Million USD | 100.0% |
| LifePoint, Inc. | -3.26 Million USD | 100.0% |
| Medite Cancer Diagnostics, Inc. | 4.9 Million USD | 100.0% |
| Paradigm Medical Industries, Inc. | 2.16 Million USD | 100.0% |
| Remedent, Inc. | -43.3 Thousand USD | 100.0% |
| Reflect Scientific, Inc. | -1.03 Million USD | 100.0% |
| SmileDirectClub, Inc. | 778.67 Million USD | 100.0% |
| Sector 10, Inc. | 163 Thousand USD | 100.0% |
| Shandong Weigao Group Medical Polymer Company Limited | -417.55 Million USD | 100.0% |
| SheerVision, Inc. | 57.34 Thousand USD | 100.0% |
| United Health Products, Inc. | 660.56 Thousand USD | 100.0% |
| Vasamed, Inc. | 22.12 Thousand USD | 100.0% |
| Wearable Health Solutions, Inc. | 2.63 Million USD | 100.0% |
| Yubo International Biotech Limited | 772.27 Thousand USD | 100.0% |